Preprint Review Version 1 This version is not peer-reviewed

Coronavirus 2019 Infection in People with Associated Co-Morbidities: Case Fatality and ACE2 Inhibitors Treatment Concerns

Version 1 : Received: 17 April 2020 / Approved: 19 April 2020 / Online: 19 April 2020 (05:42:22 CEST)

How to cite: Honardoost, M.; Aghili, R.; Khamseh, M.E. Coronavirus 2019 Infection in People with Associated Co-Morbidities: Case Fatality and ACE2 Inhibitors Treatment Concerns. Preprints 2020, 2020040331 (doi: 10.20944/preprints202004.0331.v1). Honardoost, M.; Aghili, R.; Khamseh, M.E. Coronavirus 2019 Infection in People with Associated Co-Morbidities: Case Fatality and ACE2 Inhibitors Treatment Concerns. Preprints 2020, 2020040331 (doi: 10.20944/preprints202004.0331.v1).

Abstract

The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in people with associated comorbidities. These RNA viruses containing four structural proteins usually use spike protein to enter the host cell. It has been demonstrated that Angiotensin Converting Enzyme 2 (ACE2) ,as a part of renin-angiotensin-aldosterone system (RAAS), acts as a host receptor for the virus which is the main target of therapeutic approaches. However, medications acting on RAAS can lead to serious complications especially in people with diabetes and hypertension. To avoid this, other potential treatment modalities should be used in COVID-19 patients with associated comorbidities.

Subject Areas

COVID-19; associated comorbidities; treatment; ACE2 inhibitors; Type 2 diabetes

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.